cancer-research-structural-biochemistry-2019-tracks

14 / 17

Page 32
Volume 3
August 5-6, 2019 | Singapore
CANCER RESEARCH AND PHARMACOLOGY
STRUCTURAL BIOCHEMISTRY, STEM CELLS AND MOLECULAR BIOLOGY
24th International Conference on
International Congress on
&
Cancer Research 2019 & Structural Biochemistry 2019
August 5-6, 2019
Journal of Cancer and Metastasis Research
Nanoformulated betulinic acid analogue distinctively improves colorectal carcinoma:
An advanced technology for cancer therapy
Debasmita Dutta
Jadavpur University, India
Recently Betulinic acid, a naturally occurring plant secondary metabolite, has gained significant attention due to its
antiproliferative activity over a range of cancer cells. In our previous study, we have reported a promising betulinic acid
analogue (2c) with better therapeutic efficacy than the parent molecule to colon carcinoma cells. Despite its impressive biological
activity, poor water solubility and low bioavailability creates difficulties in its pharmacological activity. To overcome these
lacunas and making it a promising drug candidate we have formulated PLGA encapsulated 2c in the present study followed
by evaluated its in vitro and in vivo therapeutic efficacy in both mice and rat colon carcinoma model. Nanoformulated drug
delivery provides several advantages over free drug such as large loading capacity, minimum drug loss, sustained drug release
and long-term in vivo stability. Additionally, due to enhanced permeability and retention effect in the tumor microenvironment,
nano sized drug molecules preferentially penetrate the tumor vessel and retain at that site which ensures minimum cytotoxicity
to normal cells. Herein we observed that nanoformulation of 2c developed a perfect nano size sphere with smooth surface
area, effective cellular uptake, 8% drug loading and in vitro sustained drug release profile. In vitro antiproliferative activity
significantly enhanced over free drug, which is measured by MTT assay, Annexin V positivity, JC1 analysis, DNA degradation
and cell cycle study. In vivo therapeutic potential measured in mice and rat model also reflects its ability as a promising drug
candidate for treatment of colon carcinoma and future potential clinical aspect.
Biography
Debasmita Dutta is presently pursuing Post-doctoral research as a DBT-Research Associate, in Department of Pharmaceutical
Technology, Jadavpur University, India. She was associated with West Bengal State University, India as a Guest Faculty in Department
of Microbiology for last three years. She has completed her PhD in Cancer Biology from CSIR-Indian Institute of Chemical Biology.
She has published her research findings in highly circulated reputed international journals like Nature Communications, ACS Applied
Biomaterials, European Journal of Medicinal Chemistry etc. She has received many scholarships and awards like Post-doctoral
fellowships from Department of Biotechnology, Government of India in 2016 and Council of Scientific and Industrial Research (CSIR),
Government of India in 2017, International Travel Grant Award from Indian Council of Medical Research (ICMR), Government of India
to attend 23rd EACR (European Association for Cancer Research) in Munich, Germany in 2014, best oral presentation award at “3rd
Pharm Tech IAPST International Conference” at Centurion University, India in 2019.